Drug
Rasagiline
Rasagiline: highest development phase Post-Market, developed by Lundbeck, Teva. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Lundbeck, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rasagiline NCT01048229 | Post-Market | Early-stage Parkinson's Disease |
| rasagiline mesylate NCT00203164 | Phase 3 | Parkinson's Disease |
| rasagiline NCT01192503 | Phase 2/3 | Restless Legs Syndrome |
Latest
No recent events.
Follow Rasagiline on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.